Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

They already completed a phase-1b combination trial of EDP-514 with a nuc (the trial that enrolled “viremic” patients) without any problems, so I presume they will advance the combination to phase-2.

That is what I figured.

Looks like I was wrong about, “pretty modest.”

No problem. Perhaps this kind of drop isn't so surprising as it was the first bit of bad news for ENTA. Still, this could represent a buying opportunity, especially if ENTA soon announces they are starting a phase II with EDP-514 + a nuc.

As far as Willyw's point, getting first is important and that is what EDP-514 + a nuc can do. ENTA can follow up with another drug that attacks a different aspect of the HepB viral lifecycle and combine it with EDP-514 + a nuc later.